Blaise Genton

Prof. Dr. Blaise Genton


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2020 in Journal of Travel Medicine
Verified
Journal Article
Closed access
IBImogen Buss
Imogen Buss
BGBlaise Genton
Blaise Genton
VDValérie D’acremont
Valérie D’acremont
Background: Numerous publications focus on fever in returning travellers, but there is no known systematic review considering all diseases, or all tropical diseases causing fever. Such a review is necessary in order to develop appropriate practice guidelines.Objectives: Primary objectives of this review were (i) to determine the aetiology of fever in travellers/migrants returning from (sub) tropical countries as well as the proportion of patients with specific diagnoses, and (ii) to assess the predictors for specific tropical diseases.Method: Embase, MEDLINE and Cochrane Library were searched with terms combining fever and travel/migrants. All studies focusing on causes of fever in returning travellers and/or clinical and laboratory predictors of tropical diseases were included. Meta-analyses were performed on frequencies of etiological diagnoses.Results: 10 064 studies were identified; 541 underwent full-text review; 30 met criteria for data extraction. Tropical infections accounted for 33% of fever diagnoses, with malaria causing 22%, dengue 5% and enteric fever 2%. Non-tropical infections accounted for 36% of febrile cases, with acute gastroenteritis causing 14% and respiratory tract infections 13%. Positive likelihood ratios demonstrated that splenomegaly, thrombocytopenia and hyperbilirubinemia were respectively 5–14, 3–11 and 5–7 times more likely in malaria than non-malaria patients. High variability of results between studies reflects heterogeneity in study design, regions visited, participants’ characteristics, setting, laboratory investigations performed and diseases included.Conclusion: Malaria accounted for one-fifth of febrile cases, highlighting the importance of rapid malaria testing in febrile returning travellers, followed by other rapid tests for common tropical diseases. High variability between studies highlights the need to harmonize study designs and to promote multi-centre studies investigating predictors of diseases, including of lower incidence, which may help to develop evidence-based guidelines. The use of clinical decision support algorithms by health workers which incorporate clinical predictors, could help standardize studies as well as improve quality of recommendations.

11 November 2023 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
BGBlaise Genton
Blaise Genton
In October 2021, a major step in the fight against malaria was achieved when WHO recommended RTS,S/AS01 (Mosquirix©; GlaxoSmithKline) malaria vaccine for the prevention of Plasmodium falciparum malaria in children 5–17 months living in regions with moderate to high transmission. 1 In July 2022, WHO issued prequalification approval for this first malaria vaccine. The evidence behind the recommendation was that three doses of the vaccine achieved a protection of 56% against clinical malaria over 1 year. A booster dose administered at 18 months after completing the primary immunization conferred 36% vaccine efficacy against symptomatic malaria and 29% efficacy against severe malaria over 4 years of follow-up in the phase 3 trial. 2 Since then, the Global Alliance for Vaccine Initiative (GAVI) board approved an initial investment of US$158 million (2022–25) to support rollout of the malaria vaccine in eligible countries.

24 November 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JSJean Marc Schwob
Jean Marc Schwob
AMAlix Miauton
Alix Miauton
DPDusan Petrovic
Dusan Petrovic
JPJean Perdrix
Jean Perdrix
NSNicolas Senn
Nicolas Senn
VDValérie D’acremont
Valérie D’acremont
Background: Nasopharyngeal antigen Rapid Diagnostic Tests (RDTs) and saliva RT-PCR have shown variable performance to detect SARS-CoV-2. Methods: In October 2020, we conducted a prospective trial involving patients presenting at testing centers with symptoms of COVID-19. We compared detection rates and performance of RDT, saliva PCR and nasopharyngeal (NP) PCR. Results: Out of 949 patients enrolled, 928 patients had all three tests. Detection rates were 35.2% (95%CI 32.2-38.4%) by RDT, 39.8% (36.6-43.0%) by saliva PCR, 40.1% (36.9-43.3%) by NP PCR, and 41.5% (38.3-44.7%) by any test. For those with viral loads (VL) ≥10 6 copies/ml, detection rates were 30.3% (27.3-33.3), 31.4% (28.4-34.5), 31.5% (28.5-34.6), and 31.6% (28.6-34.7%) respectively. Sensitivity of RDT compared to NP PCR was 87.4% (83.6-90.6%) for all positive patients and 96.5% (93.6-98.3%) for those with VL≥10 6 . Sensitivity of STANDARD-Q ® , Panbio™ and COVID-VIRO ® Ag tests were 92.9% (86.4-96.9%), 86.1% (78.6-91.7%) and 84.1% (76.9-89.7%), respectively. For those with VL≥10 6 , sensitivities were 96.6% (90.5-99.3%), 97.8% (92.1-99.7%) and 95.3% (89.4-98.5%) respectively. Specificity of RDT was 100% (99.3-100%) compared to any PCR. RDT sensitivity was similar <4 days (87.8%) and ≥4 days (85.7%) after symptoms onset (p=0.6). Sensitivities of saliva and NP PCR were 95.7% (93.1-97.5%) and 96.5% (94.1-98.1%), respectively, compared to the other PCR. Conclusions: The high performance of RDTs allows rapid identification of COVID cases with immediate isolation of the vast majority of contagious individuals. RDT could be a game changer in primary care practices, and even more so in resource-constrained settings. PCR on saliva can replace NP PCR. ClinicalTrial.gov Identifier: NCT04613310

5 February 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
RTRainer Tan
Rainer Tan
FKFrank Kagoro
Frank Kagoro
GLGillian A. Levine
Gillian A. Levine
JMJohn Masimba
John Masimba
JSJosephine Samaka
Josephine Samaka
KKKristina Keitel
Kristina Keitel
Children with malnutrition compared with those without are at higher risk of infection, with more severe outcomes. How clinicians assess nutritional risk factors in febrile children in primary care varies. We conducted a post hoc subgroup analysis of febrile children with severe malnutrition enrolled in a randomized, controlled trial in primary care centers in Tanzania. The clinical outcome of children with severe malnutrition defined by anthropometric measures and clinical signs was compared between two electronic clinical diagnostic algorithms: ePOCT, which uses weight-for-age and mid-upper arm circumference to identify and manage severe malnutrition, and ALMANACH, which uses the clinical signs of edema of both feet and visible severe wasting. Those identified as having severe malnutrition by the algorithms in each arm were prescribed antibiotics and referred to the hospital. From December 2014 to February 2016, 106 febrile children were enrolled and randomized in the parent study, and met the criteria to be included in the present analysis. ePOCT identified 56/57 children with severe malnutrition using anthropometric measures, whereas ALMANACH identified 2/49 children with severe malnutrition using clinical signs. The proportion of clinical failure, defined as the development of severe symptoms by day 7 or persisting symptoms at day 7 (per-protocol), was 1.8% (1/56) in the ePOCT arm versus 16.7% (8/48) in the Algorithm for the MANagement of Childhood illnesses arm (risk difference −14.9%, 95% CI −26.0%, −3.8%; risk ratio 0.11, 95% CI 0.01, 0.83). Using anthropometric measures to identify and manage febrile children with severe malnutrition may have resulted in better clinical outcomes than by using clinical signs alone.

22 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MVManon Vouga
Manon Vouga
LPLéo Pomar
Léo Pomar
ASAntoni Soriano-Arandes
Antoni Soriano-Arandes
CRCarlota Rodó
Carlota Rodó
Anna GoncéAnna Goncé
Anna Goncé
Alice PanchaudAlice Panchaud
Alice Panchaud
In this multicentre cohort study, we evaluated the risks of maternal ZIKV infections and adverse pregnancy outcomes among exposed travellers compared to women living in areas with ZIKV circulation (residents). The risk of maternal infection was lower among travellers compared to residents: 25.0% (n = 36/144) versus 42.9% (n = 309/721); aRR 0.6; 95% CI 0.5–0.8. Risk factors associated with maternal infection among travellers were travelling during the epidemic period (i.e., June 2015 to December 2016) (aOR 29.4; 95% CI 3.7–228.1), travelling to the Caribbean Islands (aOR 3.2; 95% CI 1.2–8.7) and stay duration >2 weeks (aOR 8.7; 95% CI 1.1–71.5). Adverse pregnancy outcomes were observed in 8.3% (n = 3/36) of infected travellers and 12.7% (n = 39/309) of infected residents. Overall, the risk of maternal infections is lower among travellers compared to residents and related to the presence of ongoing outbreaks and stay duration, with stays <2 weeks associated with minimal risk in the absence of ongoing outbreaks.

25 August 2026 in Malaria Journal
Verified
Journal Article
Open access
PDF file
EAElizabeth A. Ashley
Elizabeth A. Ashley
EBEmmanuel Baron
Emmanuel Baron
MAMarielle Karine BOUYOU AKOTET
Marielle Karine BOUYOU AKOTET
RBRebekah Burrow
Rebekah Burrow
GCGwenaelle Carn
Gwenaelle Carn
NWNicholas J. White
Nicholas J. White
Introduction: A combination of mefloquine associated with artesunate (AS-MQ) was the first artemisinin-based combination therapy (ACT) to be used widely for acute uncomplicated P. falciparum malaria. Methods: Individual patient data from 31 studies of patients with uncomplicated falciparum malaria treated with various AS-MQ regimens (target mefloquine dose 25 mg/kg), conducted in Asia, Africa and South America, were pooled and analysed to investigate the effects of MQ mg/kg dosing on malaria recurrence and other clinical, parasitological and tolerability endpoints. Results: A total of 6,761 patients were enrolled in clinical studies conducted between 1995 and 2018; the majority (74%) were from Asia. The median age of study participants was 18 years (interquartile range IQR 8–30 years), of whom 13.5% (915/6761) were aged less than 5 years old. Participants received an estimated median [range] total mg/kg dose of mefloquine and artesunate of 25 [6.8–60] and 12 [3.6–33.3] respectively, and 1,572 (23.4%) participants were treated with the coformulation. The PCR-corrected recrudescence rate 42 days after any ASMQ treatment was 2.4% for patients enrolled in Asia and 2.5% in Africa, before artemisinin resistance emerged. Corresponding rates in children aged 1 to < 5 years were 2.9% and 3.3%. After adjusting for background artemisinin resistance, the hazard of recrudescence was higher in children aged 1 to < 5 years than in adults in Asia, but not in Africa (Asia, HR 3.01, 95%CI 1.60–5.64, p < 0.001; Africa HR 5.18, 95% CI 0.61–44.28, p = 0.133). There was only one recrudescent infection in South America. A significant MQ dose–effect was observed in Asia in patients treated with 3-dose regimens (AHR 0.89, 95% CI 0.83–0.96, p = 0.003 for 1 mg/kg increase in dose). Vomiting rates within an hour of dosing were highest in children 1- 5 years of age (n = 140) at 3.4% doses (13/378) compared to 1.7% (20/1,168) in children 5–11 years (n = 476), and 1.1% (47/4,191) in patients 12 years of age or older (n = 2027) (p < 0.001, test for trend). Conclusion: AS-MQ administered over three days is a highly efficacious ACT in low to moderate transmission areas without artemisinin resistance. While further optimisation of the mefloquine dose in the coformulation in children aged 1–5 years could be considered, dose-related early vomiting is highest in this age group and may preclude this.